This has led to speculation that treatment of TSC hamartomas with mTORC1 inhibitors might lead to restoration of AKT activation, as seen in vitro with treatment of TSC1/TSC2 null cells, and in some patients with malignant disease [12], which may compromise clinical benefit. The gene discussed is TSC2; the disease is tuberous sclerosis.